Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors?
| dc.contributor.author | Berezin, A. E. | |
| dc.contributor.author | Berezin, A. A. | |
| dc.contributor.author | Березін, Олександр Євгенійович | |
| dc.date.accessioned | 2021-05-14T05:32:59Z | |
| dc.date.available | 2021-05-14T05:32:59Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Current clinical guidelines for heart failure (HF) contain a new therapeutic strategy for a certain type of HF. There is a large body of evidence for the fact that certain types of drugs called sodiumglucose co-transporter 2 inhibitors may significantly improve outcomes in patients with this type of HF who received a different group of drugs. The review discusses the features of sodium-glucose co-transporter 2 inhibitors that make them successful in improving the outcomes in patients with HF. First draft submitted: 29 October 2020; Accepted for publication: 21 December 2020; Published online: 22 February 2021 | uk_UK |
| dc.identifier.citation | Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors? / A. E. Berezin, A. А. Berezin // Future Cardiology. - 2021. - N 17(3). - P. 497–506. https://doi.org/10.2217/fca-2020-0178 | uk_UK |
| dc.identifier.uri | https://zsmu.rosbai.com/handle/123456789/13638 | |
| dc.language.iso | en | uk_UK |
| dc.subject | angiotensin receptor neprilysin inhibitor | uk_UK |
| dc.subject | clinical outcomes | uk_UK |
| dc.subject | heart failure | uk_UK |
| dc.subject | prognosis | uk_UK |
| dc.subject | sodium-glucose co-transporter 2 inhibitors | uk_UK |
| dc.title | Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors? | uk_UK |
| dc.type | Article | uk_UK |